Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

Abstract: The past few years have witnessed a surge in the number of advanced network adapters, known as "SmartNICs", that offer additional functionalities beyond standard packet processing ...

You've got 3 seconds. That's how long a potential customer can decide if they trust your business. And in those critical moments, your logo is doing the heavy lifting. I've seen businesses transform ...